Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


Antiinfectives are also classified in the following groups:
A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R02AB Antibiotics
S03 Eye and ear preparations with antiinfectives
Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use.
Inhaled antiinfectives are classified in J.

The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).


This group comprises drugs mainly used for the treatment of tuberculosis or lepra. However, streptomycins are classified in J01G - Aminoglycoside antibacterials. Streptomycin in combination with antimycobacterials are classified in J04AM.


The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.

J04AA Aminosalicylic acid and derivatives

Calcium aluminoparaaminosalicylate is classified together with calcium aminosalicylate in J04AA03.

J04AB Antibiotics

This group comprises antibiotics specifically used in tuberculosis, except streptomycin - see comment under J04AM. Other antibiotics, see J01 -Antibacterials for systemic use.

The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.

J04AC Hydrazides

Combinations of isoniazid and rifampicin or other tuberculostatics are classified in J04AM.

J04AD Thiocarbamide derivatives
J04AK Other drugs for treatment of tuberculosis
J04AM Combinations of drugs for treatment of tuberculosis

Combinations of drugs classified in J04AA - J04AK are classified in this group (e. g. isoniazid + rifampicin).
Combinations of antimycobacterials and antibacterials for systemic use (J01) are classified here.

Last updated: 2023-01-23